HC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $7 Price Target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and maintains $7 price target.

byBenzinga Newsdesk

March 14, 2023

1 minute read

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Oncternal Therapeutics (NASDAQ:ONCT) with a Buy and maintains $7 price target.

Intuit Sees Q1 Adj. EPS $0.94-$0.99 vs $1.14 Est.

By Bill Haddad

Today, 5:45 PM

Intuit announced guidance for the first quarter of fiscal year 2022, which ends Oct. 31. The company expects: Revenue growth of approximately 36 to 38 percent, including Credit Karma. GAAP

INTU

Apple Card Users Can Now Get Interest On Daily Rewards In A Savings Account

By Shivdeep Dhaliwal

Today, 5:45 PM

Apple Inc (NASDAQ: AAPL) introduced new savings account for users of its credit card on Thursday.

AAPL

Rocket Pharma Early Monday Reported Will Give Updated Data From Ongoing Phase 1 Trial Of RP-A501 In Danon Disease At American Heart Association Sessions Nov. 13 At 8 a.m. EST

By Benzinga Newsdesk

Today, 5:45 PM

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKT), a clinical-stage company advancing an integrated and sustainable pipeline of genetic therapies for rare childhood disorders, today announces that updated data from the ongoing

RCKT

Analyst Ratings

What 7 Analyst Ratings Have To Say About AbbVie

By Benzinga Insights

Today, 5:45 PM

Over the past 3 months, 7 analysts have published their opinion on AbbVie (NYSE:ABBV) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

ABBV

HC Wainwright & Co. Reiterates Buy on Oncternal Therapeutics, Maintains $7 Price Target

Related Posts

Intuit Sees Q1 Adj. EPS $0.94-$0.99 vs $1.14 Est.

Apple Card Users Can Now Get Interest On Daily Rewards In A Savings Account

Rocket Pharma Early Monday Reported Will Give Updated Data From Ongoing Phase 1 Trial Of RP-A501 In Danon Disease At American Heart Association Sessions Nov. 13 At 8 a.m. EST

What 7 Analyst Ratings Have To Say About AbbVie